CASP1 and Cognitive impairment: VX765, a blood-brain barrier permeable and likely non-toxic Casp1 inhibitor, blocks the Nlrp1-caspase1-caspase6 pathway, attenuating cognitive deficits and microglial activation caused by caspase-6 [59, 81, 82].